{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:14:45Z","timestamp":1791494085408,"version":"4.3.4"},"reference-count":6,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Card Fail Rev"],"DOI":"10.15420\/cfr.2025.16","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T14:58:41Z","timestamp":1753369121000},"source":"Crossref","is-referenced-by-count":3,"title":["The Aldosterone Story: New Chapters"],"prefix":"10.15420","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9512-1718","authenticated-orcid":false,"given":"Vijay","family":"Chopra","sequence":"first","affiliation":[{"name":"Heart Failure Programme, Max Super Speciality Hospital, Saket, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Butler J, Anker SD, Lund LH, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J 2022;43:4362\u201373. https:\/\/doi.org\/10.1093\/eurheartj\/ehac401; PMID: 35900838.","DOI":"10.1016\/j.cardfail.2023.10.295"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia. The HARMONIZE randomized clinical trial. JAMA 2014;312:2223\u201333. https:\/\/doi.org\/10.1001\/jama.2014.15688; PMID: 25402495.","DOI":"10.1001\/jama.2014.15688"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020;383:2219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2025845; PMID: 33264825.","DOI":"10.1056\/nejmoa2025845"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N\u00a0Engl J Med 2021;385:2252\u201363. https:\/\/doi.org\/10.1056\/NEJMoa2110956; PMID: 34449181.","DOI":"10.1056\/nejmoa2110956"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2024;391:1475\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2407107; PMID: 39225278.","DOI":"10.1056\/NEJMe2410904"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Perl S, Azizi M, Bakris G, et al. Rationale and design of phase 3 trial for baxdrostat, a novel highly selective aldosterone synthetase inhibitor. J Hypertens 2024;42(Suppl 1):e259\u201360. https:\/\/doi.org\/10.1097\/01.hjh.0001022164.52364.06.","DOI":"10.1097\/01.hjh.0001022164.52364.06"}],"container-title":["Cardiac Failure Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2025.16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T14:58:42Z","timestamp":1753369122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2025.16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":6,"URL":"https:\/\/doi.org\/10.15420\/cfr.2025.16","relation":{},"ISSN":["2057-7559","2057-7540"],"issn-type":[{"value":"2057-7559","type":"electronic"},{"value":"2057-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"article-number":"e17"}}